SEC Form 4 · accession 0001209191-19-008117
Dova Pharmaceuticals Inc. · DOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven M. Goldman
Director
Period of report
Feb 5, 2019
Accepted (ET)
Feb 7, 2019 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001685071
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 5, 2019 | A | 7,528 | — | A | 132,529 | D | |
| Common StockF3 | holding | — | — | — | 5,000 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a restricted stock unit ("RSU") award that vests 50% on each of June 30, 2019 and 25% on each of September 30, 2019 and December 31, 2019.
- F2Each RSU represents a contingent right to receive one share of Issuer common stock.
- F3These shares are held by the Steven M. Goldman Family LLC (the "LLC"), of which the Reporting Person is the Managing Member. The voting and investment decisions of the LLC are made by an independent external asset manager. The Reporting Person disclaims beneficial ownership of the shares held by the LLC except to the extent of his pecuniary interest in the LLC, if any, and the inclusion of these shares on this report shall not be deemed an admission that the Reporting Person beneficially owns the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or any other purpose.